Review Article | Published:

CAR T cells for infection, autoimmunity and allotransplantation

Nature Reviews Immunologyvolume 18pages605616 (2018) | Download Citation

Abstract

Chimeric antigen receptors (CARs) have shown remarkable ability to re-direct T cells to target CD19-expressing tumours, resulting in remission rates of up to 90% in individuals with paediatric acute lymphoblastic lymphoma. Lessons learned from these clinical trials of adoptive T cell therapy for cancer, as well as investments made in manufacturing T cells at commercial scale, have inspired researchers to develop CARs for additional applications. Here, we explore the challenges and opportunities of using this technology to target infectious diseases such as with HIV and undesired immune responses such as autoimmunity and transplant rejection. Despite substantial obstacles, the potential of CAR T cells to enable cures for a wide array of disease settings could be transformational for the medical field.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    McMichael, A. T cell responses and viral escape. Cell 93, 673–676 (1998).

  2. 2.

    Roberts, M. R. et al. Targeting of human immunodeficiency virus-infected cells by CD8 + T lymphocytes armed with universal T cell receptors. Blood 84, 2878–2889 (1994).

  3. 3.

    Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl Med. 4, 132ra153 (2012).

  4. 4.

    Castelli, J. C., Deeks, S. G., Shiboski, S. & Levy, J. A. Relationship of CD8+ T cell noncytotoxic anti-HIV response to CD4+ T cell number in untreated asymptomatic HIV-infected individuals. Blood 99, 4225–4227 (2002).

  5. 5.

    Mitsuyasu, R. T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-nfected subjects. Blood 96, 785–793 (2000).

  6. 6.

    Walker, R. E. et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96, 467–474 (2000).

  7. 7.

    June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).

  8. 8.

    Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).

  9. 9.

    June, C. H., Blazar, B. R. & Riley, J. L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9, 704–716 (2009).

  10. 10.

    Barrett, D. M., Grupp, S. A. & June, C. H. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J. Immunol. 195, 755–761 (2015).

  11. 11.

    Cheng, Y., Wong, M. T., van der Maaten, L. & Newell, E. W. Categorical analysis of human T cell heterogeneity with one-dimensional soli-expression by nonlinear stochastic embedding. J. Immunol. 196, 924–932 (2016).

  12. 12.

    Rainwater-Lovett, K., Uprety, P. & Persaud, D. Advances and hope for perinatal HIV remission and cure in children and adolescents. Curr. Opin. Pediatr. 28, 86–92 (2016).

  13. 13.

    Saez-Cirion, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLOS Pathog. 9, e1003211 (2013).

  14. 14.

    Jones, R. B. & Walker, B. D. HIV-specific CD8+ T cells and HIV eradication. J. Clin. Invest. 126, 455–463 (2016).

  15. 15.

    Fesnak, A. D., June, C. H. & Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566–581 (2016).

  16. 16.

    van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499–509 (2015).

  17. 17.

    Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).

  18. 18.

    Gomes-Silva, D. et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 21, 17–26 (2017).

  19. 19.

    Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380–390 (2016).

  20. 20.

    Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769–777 (2002).

  21. 21.

    Leibman, R. S. et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLOS Pathog. 13, e1006613 (2017).

  22. 22.

    Liu, B. et al. Chimeric antigen receptor T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4+ T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy. J. Virol. 90, 9712–9724 (2016).

  23. 23.

    Hale, M. et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25, 570–579 (2017).

  24. 24.

    Liu, L. et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J. Virol. 89, 6685–6694 (2015).

  25. 25.

    Ghanem, M. H. et al. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity. Cytotherapy 20, 407–419 (2018).

  26. 26.

    Figdor, C. G., van Kooyk, Y. & Adema, G. J. C-Type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2, 77–84 (2002).

  27. 27.

    Ip, W. K., Takahashi, K., Ezekowitz, R. A. & Stuart, L. M. Mannose-binding lectin and innate immunity. Immunol. Rev. 230, 9–21 (2009).

  28. 28.

    Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).

  29. 29.

    Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl Med. 5, 177ra138 (2013).

  30. 30.

    Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl Med. 7, 303ra139 (2015).

  31. 31.

    Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).

  32. 32.

    Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322–3331 (2017).

  33. 33.

    Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

  34. 34.

    Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. Immunity 33, 451–463 (2010).

  35. 35.

    Wang, X. et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin. Cancer Res. 21, 2993–3002 (2015).

  36. 36.

    Sun, J. et al. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J. Immunother. Cancer 3, 5 (2015).

  37. 37.

    Nakazawa, Y. et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T cells expressing HER2-specific chimeric antigen receptor. Mol. Ther. 19, 2133–2143 (2011).

  38. 38.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/show/NCT01430390 (2011).

  39. 39.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/show/NCT00709033 (2008).

  40. 40.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/show/NCT01109095 (2010).

  41. 41.

    US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/show/NCT03186118 (2017).

  42. 42.

    Gray, G. E., Laher, F., Lazarus, E., Ensoli, B. & Corey, L. Approaches to preventative and therapeutic HIV vaccines. Curr. Opin. Virol. 17, 104–109 (2016).

  43. 43.

    Leibman, R. S. & Riley, J. L. Engineering T cells to functionally cure HIV-1 infection. Mol. Ther. 23, 1149–1159 (2015).

  44. 44.

    Perez, E. E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808–816 (2008).

  45. 45.

    Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).

  46. 46.

    Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).

  47. 47.

    Sather, B. D. et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl Med. 7, 307ra156 (2015).

  48. 48.

    Wang, J. et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 44, e30 (2016).

  49. 49.

    Maier, D. A. et al. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum. Gene Ther. 24, 245–258 (2013).

  50. 50.

    MacLean, A. G. et al. A novel real-time CTL assay to measure designer T cell function against HIV Env+ cells. J. Med. Primatol. 43, 341–348 (2014).

  51. 51.

    Kamata, M. et al. Ectopic expression of anti-HIV-1 shRNAs protects CD8+ T cells modified with CD4zeta CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochem. Biophys. Res. Commun. 463, 216–221 (2015).

  52. 52.

    Zhen, A. et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. PLOS Pathog. 13, e1006753 (2017). This paper reports HIV-specific CAR T cell therapy using haematopoietic stem cells in a non-human primate model of HIV infection.

  53. 53.

    Leslie, G. J. et al. Potent and broad inhibition of HIV-1 by a peptide from the gp41 heptad repeat-2 domain conjugated to the CXCR4 amino terminus. PLOS Pathog. 12, e1005983 (2016).

  54. 54.

    Frigault, M. J. et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 3, 356–367 (2015).

  55. 55.

    Levine, B. L. et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939–1943 (1996).

  56. 56.

    Richardson, M. W., Jadlowsky, J., Didigu, C. A., Doms, R. W. & Riley, J. L. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J. Immunol. 189, 3815–3821 (2012).

  57. 57.

    Riley, J. L. et al. Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J. Exp. Med. 191, 1987–1997 (2000).

  58. 58.

    Riley, J. L. et al. Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J. Immunol. 158, 5545–5553 (1997).

  59. 59.

    Carroll, R. G. et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 276, 273–276 (1997).

  60. 60.

    Mendelson, A. & Frenette, P. S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat. Med. 20, 833–846 (2014).

  61. 61.

    Zhen, A. & Kitchen, S. Stem-cell-based gene therapy for HIV infection. Viruses 6, 1–12 (2013).

  62. 62.

    Kitchen, S. G. et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLOS Pathog. 8, e1002649 (2012).

  63. 63.

    Zhen, A. et al. Stem-cell based engineered immunity against HIV infection in the humanized mouse model. J. Vis. Exp. 113, e54048 (2016).

  64. 64.

    Zhen, A. et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol. Ther. 23, 1358–1367 (2015).

  65. 65.

    Tran, A. C., Zhang, D., Byrn, R. & Roberts, M. R. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J. Immunol. 155, 1000–1009 (1995).

  66. 66.

    Riley, J. L. & Montaner, L. J. Cell-mediated immunity to target the persistent human immunodeficiency virus reservoir. J. Infect. Dis. 215, S160–S171 (2017).

  67. 67.

    Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501 (2012).

  68. 68.

    Deeks, S. G. HIV: shock and kill. Nature 487, 439–440 (2012).

  69. 69.

    Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).

  70. 70.

    Sogaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLOS Pathog. 11, e1005142 (2015).

  71. 71.

    Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890 (2014).

  72. 72.

    Huang, S. H. et al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J. Clin. Invest. 128, 876–889 (2018).

  73. 73.

    Pollack, R. A. et al. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape. Cell Host Microbe 21, 494–506 (2017).

  74. 74.

    Bruner, K. M. et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat. Med. 22, 1043–1049 (2016).

  75. 75.

    Banga, R. et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754–761 (2016).

  76. 76.

    Perreau, M. et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210, 143–156 (2013).

  77. 77.

    Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309–314 (2000).

  78. 78.

    Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87, 1037–1047 (1996).

  79. 79.

    Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015). This paper shows that B cell follicles in lymphoid tissue are sanctuary sites for persistent SIV replication despite the presence of SIV-specific CD8 + T cells.

  80. 80.

    Reuter, M. A. et al. HIV-specific CD8+ T cells exhibit reduced and differentially regulated cytolytic activity in lymphoid tissue. Cell Rep. 21, 3458–3470 (2017). This paper highlights that HIV-specific CD8 + T cells in lymphoid tissue have reduced cytolytic activity, which indicates that lymph nodes are a site of immune privilege against CD8 + T cell-mediated cytotoxicity.

  81. 81.

    Ayala, V. I. et al. CXCR5-dependent entry of CD8 T cells into Rhesus Macaque B-cell follicles achieved through T-cell engineering. J. Virol. 91, e02507-16 (2017).

  82. 82.

    Webb, G. M. et al. The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B cell follicles. Blood Adv. 2, 76–84 (2018).

  83. 83.

    Jones, R. B. et al. A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLOS Pathog. 12, e1005545 (2016).

  84. 84.

    Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).

  85. 85.

    Chen, F. et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J. Immunol. Methods 434, 1–8 (2016).

  86. 86.

    Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016). This paper provides a description of CAAR T cells, which showed specific killing of autoimmune B cells.

  87. 87.

    Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLOS One 8, e57838 (2013).

  88. 88.

    Trzonkowski, P. et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127 T regulatory cells. Clin. Immunol. 133, 22–26 (2009).

  89. 89.

    Brunstein, C. G. et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117, 1061–1070 (2011).

  90. 90.

    Brunstein, C. G. et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127, 1044–1051 (2016). This study shows that large-scale, GMP-compliant expansion of polyclonal Treg cell populations using artificial antigen-presenting cells can be used to prevent the development of GVHD in bone marrow transplant recipients.

  91. 91.

    Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl Med. 7, 315ra189 (2015). By giving polyclonal T reg cell infusions to patients with type 1 diabetes, the authors show that the clinical expansion process can improve the in vitro suppressive function of T reg cells and correct intrinsic patient-associated T reg cell deficits. In addition, the authors show that long-term, stable persistence of infused T reg cells can occur in vivo.

  92. 92.

    Hippen, K. L. et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci. Transl Med. 3, 83ra41 (2011).

  93. 93.

    McKenna, D. H. Jr. et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 19, 250–262 (2017).

  94. 94.

    Tang, Q. et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199, 1455–1465 (2004).

  95. 95.

    Moran, A. E. et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208, 1279–1289 (2011).

  96. 96.

    Tabares, P. et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur. J. Immunol. 44, 1225–1236 (2014).

  97. 97.

    Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723–735 (2005).

  98. 98.

    Elinav, E., Waks, T. & Eshhar, Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 134, 2014–2024 (2008). This is an early report of CAR T reg cells, showing specificity, function, bystander suppression and trafficking.

  99. 99.

    Elinav, E., Adam, N., Waks, T. & Eshhar, Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 136, 1721–1731 (2009).

  100. 100.

    Blat, D., Zigmond, E., Alteber, Z., Waks, T. & Eshhar, Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol. Ther. 22, 1018–1028 (2014).

  101. 101.

    Fransson, M. et al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflamm. 9, 112 (2012).

  102. 102.

    Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).

  103. 103.

    Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007 (2009). The authors show that T reg cells in autoimmune environments can become pathogenic ‘ex-FOXP3’ cells, highlighting a major safety concern for the use of CAR T reg cells.

  104. 104.

    Magnuson, A. M. et al. Population dynamics of islet-infiltrating cells in autoimmune diabetes. Proc. Natl Acad. Sci. USA 112, 1511–1516 (2015).

  105. 105.

    Riley, J. L., June, C. H. & Blazar, B. R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30, 656–665 (2009).

  106. 106.

    Hoffmann, P. et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T cell lines upon in vitro expansion. Blood 108, 4260–4267 (2006).

  107. 107.

    Fu, S. et al. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am. J. Transplant. 4, 65–78 (2004).

  108. 108.

    Hippen, K. L. et al. Umbilical cord blood regulatory T cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112, 2847–2857 (2008).

  109. 109.

    Seay, H. R. et al. Expansion of human Tregs from cryopreserved umbilical cord blood for GMP-compliant autologous adoptive cell transfer therapy. Mol. Ther. Methods Clin. Dev. 4, 178–191 (2017).

  110. 110.

    Golovina, T. N. et al. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLOS One 6, e15868 (2011).

  111. 111.

    Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911 (2009).

  112. 112.

    Polansky, J. K. et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38, 1654–1663 (2008).

  113. 113.

    Putnam, A. L. et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am. J. Transplant 13, 3010–3020 (2013).

  114. 114.

    Plesa, G. et al. TCR affinity and specificity requirements for human regulatory T cell function. Blood 119, 3420–3430 (2012).

  115. 115.

    Bonifant, C. L., Jackson, H. J., Brentjens, R. J. & Curran, K. J. Toxicity and management in CAR T cell therapy. Mol. Ther. Oncolyt. 3, 16011 (2016).

  116. 116.

    Jonuleit, H. et al. Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to conventional CD4+ T helper cells. J. Exp. Med. 196, 255–260 (2002).

  117. 117.

    Okada, M., Kanamori, M., Someya, K., Nakatsukasa, H. & Yoshimura, A. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. Epigenetics Chromatin 10, 24 (2017).

  118. 118.

    Chai, J. G. et al. Regulatory T cells, derived from naive CD4 + CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 79, 1310–1316 (2005).

  119. 119.

    Jaeckel, E., von Boehmer, H. & Manns, M. P. Antigen-specific FoxP3-transduced T cells can control established type 1 diabetes. Diabetes 54, 306–310 (2005).

  120. 120.

    Bour-Jordan, H. & Bluestone, J. A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41–66 (2009).

  121. 121.

    MacDonald, K. G. et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Invest. 126, 1413–1424 (2016). An early paper showing how HLA-specific CARs can redirect T reg cells to promote tolerance in MHC-mismatched transplant recipients.

  122. 122.

    Boardman, D. A. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am. J. Transplant 17, 931–943 (2017).

  123. 123.

    Noyan, F. et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am. J. Transplant 17, 917–930 (2017).

  124. 124.

    Yoon, J. et al. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T and B cell responses to FVIII. Blood 129, 238–245 (2017).

  125. 125.

    Pierini, A. et al. T cells expressing chimeric antigen receptor promote immune tolerance. JCI Insight 2, e92865 (2017).

  126. 126.

    Salomon, B. et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440 (2000).

  127. 127.

    Paulos, C. M. et al. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol. Res. 42, 182–196 (2008).

  128. 128.

    Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).

  129. 129.

    Claus, C. et al. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 72, 3664–3676 (2012).

  130. 130.

    Akbari, O. et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8, 1024–1032 (2002).

  131. 131.

    June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. Sci. Transl Med. 7, 280ps287 (2015).

  132. 132.

    Pan, J. et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31, 2587 (2017).

  133. 133.

    Brunstein, C. G. et al. Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. Biol. Blood Marrow Transplant 19, 1271–1273 (2013).

  134. 134.

    Riley, J. L. et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl Acad. Sci. USA 99, 11790–11795 (2002).

  135. 135.

    Lawlor, D. A., Ward, F. E., Ennis, P. D., Jackson, A. P. & Parham, P. HLA-A and B polymorphisms predate the divergence of humans and chimpanzees. Nature 335, 268–271 (1988).

  136. 136.

    Benitez, C. et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 58, 1824–1835 (2013).

  137. 137.

    Feng, S. et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 307, 283–293 (2012).

  138. 138.

    Todo, S. et al. A pilot study of operational tolerance with a regulatory T cell-based cell therapy in living donor liver transplantation. Hepatology 64, 632–643 (2016).

Download references

Acknowledgements

The authors thank members of the Riley laboratory for their thoughtful comments and support and members of the Center of Cellular Immunotherapies at the University of Pennsylvania for providing an exciting environment in which to study chimeric antigen receptor T cell therapy.

Reviewer information

Nature Reviews Immunology thanks S. Kitchen and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

Author notes

  1. These authors contributed equally: Colby R. Maldini, Gavin I. Ellis.

Affiliations

  1. Department of Microbiology and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    • Colby R. Maldini
    • , Gavin I. Ellis
    •  & James L. Riley

Authors

  1. Search for Colby R. Maldini in:

  2. Search for Gavin I. Ellis in:

  3. Search for James L. Riley in:

Contributions

All authors researched data for the article, discussed its content and wrote, reviewed and edited it before submission.

Competing interests

J.L.R. holds equity in Tmunity Therapeutics. The other authors declare no competing interests.

Corresponding author

Correspondence to James L. Riley.

Glossary

Chimeric antigen receptor

(CAR). A synthetic receptor engineered to be expressed on the surface of T cells or other immune cells to redirect cellular specificity.

HIV reservoir

Persistent HIV that remains transcriptionally silent as inactive provirus within infected CD4+ T cells despite effective combination antiretroviral therapy.

Combination antiretroviral therapy

(cART). Therapy that consists of two or more active drugs with different mechanisms of action that are used to subdue HIV replication.

Exhaustion

A state of T cell dysfunction that develops over time with repeated exposure to cognate antigen, for example, during chronic infection with a virus such as HIV.

Broadly neutralizing antibodies

(bNAbs). Antibodies that have the unique ability to neutralize and prevent infection with multiple and diverse strains of HIV.

Homology-directed repair

(HDR). A mechanism in cells to repair double-stranded DNA breaks using a DNA donor template with homologous sequences flanking the break site.

MegaTAL nuclease

A sequence-specific endonuclease with a DNA-binding domain that promotes efficient cleavage of genomic DNA with a high degree of fidelity.

Good manufacturing practice

(GMP). A series of guidelines enforced by the Food and Drug Administration in the United States, and other similar bodies elsewhere, regarding the manufacturing of safe biological therapeutic agents.

Tonic signalling

Low-level signalling caused by antigen-independent clustering of receptor molecules in the basal state of a cell.

Latency-reversing agents

(LRAs). Pharmacological agents that induce HIV transcription from cells harbouring HIV provirus.

T follicular helper cells

(TFH cells). A specialized CD4+ T cell subset that primarily resides in the B cell follicles of lymphoid tissue to aid the development of the humoral immune response.

Elite controller

A rare population of HIV-infected individuals who can spontaneously control HIV replication in the absence of combination antiretroviral therapy.

Cytokine storm

The excessive production of pro-inflammatory cytokines often induced by the over-activation of immune cells.

Chimeric autoantibody receptors

(CAARs). Chimeric antigen receptor-like receptors whose extracellular domain consists of the protein target of a B cell-mediated autoimmune response.

Pemphigus vulgaris

An antibody-mediated autoimmune disease that causes blistering of the skin.

Desmogleins

Components of cell–cell adhesion complexes that form desmosomes under antibody-mediated attack in patients with pemphigus vulgaris.

Bystander suppression

The ability of a regulatory T (Treg) cell to suppress effector T cell responses directed at an antigen distinct from the antigen that stimulated the Treg cell.

Treg cell-specific demethylated region

A conserved region of intron 1 of FOXP3 that is demethylated in cells that are stably committed to the regulatory T (Treg) cell lineage.

Suicide switches

Engineered logic gates used as a safety mechanism that cause cells to undergo apoptosis when certain conditions are met. Many suicide switches activate in response to exogenous drugs.

Infectious tolerance

A phenomenon by which regulatory T cell activation can impart suppressive activity to effector T cells.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41577-018-0042-2